Skip to main content
OpenTrials
Completed

NCT Number: NCT01861600

Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas

The primary efficacy objective was to determine and compare stool composition (stool soap and non-soap fatty acids, total fatty acids, minerals, and other stool constituents) among the feeding groups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

7 day–14 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Asian Hospital and Medical Center

Metro Manila, Alabang, 1780, Philippines

About this study

The purpose of this study is to evaluate the effects of term infant formula containing high 2-palmitic vegetable oil on stool composition and characteristics and to investigate the effect of both high 2-palmitic vegetable oil and oligofructose in infant formula on stool softness and bacteria. Because some studies demonstrate the benefit of high concentrations of a non-digestible carbohydrate in the formula, we will study 2 concentrations of added oligofructose.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, term (no less than 37 weeks, 0 days and no greater than 42 weeks, 0 days) singleton infants, between 7 days and 14 day post natal age
  • Weight for age ≥5th percentile according to Filipino growth tables/charts.
  • HM infants were exclusively consuming and tolerating HM
  • Mother must have made the decision to continue to exclusively breastfeed.
  • Formula-fed infants were exclusively consuming and tolerating a cow's milk infant formula
  • Parent/guardian must have previously made the decision to continue to exclusively formula feed

Exclusion criteria

  • Infants who are receiving any amount of supplemental HM with infant formula feeding or visa versa
  • Infants who are receiving any infant formula containing pro- or prebiotics
  • Family history of siblings with documented cow's milk protein intolerance/allergy
  • Conditions requiring infant feedings other than those specified in the protocol
  • Major congenital malformations (e.g. cleft palate, hemangiomas, extremity malformation)
  • Suspected or documented systemic or congenital infections (e.g. human immunodeficiency virus, cytomegalovirus)
  • Evidence of significant cardiac, respiratory, endocrinologic, hematologic, gastrointestinal, or other systemic diseases
  • Infants who have received any experimental treatment, participated in any other clinical trial, or received any other investigational intervention unrelated to this trial, prior to enrollment
  • Infants of any ancillary personnel connected with the study or the infants of first and second-degree relatives (parents, brothers, sisters, children, or grandchildren) of ancillary personnel
  • Presently receiving or have received any medication(s) which are known or suspected to affect fat digestion, absorption and/or metabolism (e.g., pancreatic enzymes), any vitamin and/or mineral supplements which contain calcium, all antibiotics and antifungal medications (except topical), suppositories, bismuth-containing medications, herbal supplements, or medications which may neutralize or suppress gastric acid secretion
  • HM-fed infants whose mothers are presently receiving or have received any antibiotics or antifungal medications (except topical), post partum

Treatment and study plan

S-26 Gold

Other

(13.4 g/L protein) with 100% Fat Blend A

S-26 Gold EF1

Other

(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend

S-26 Gold EF2

Other

(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose

S-26 Gold EF3

Other

(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose

human milk

Other

Human Milk

Primary outcomes

  1. Stool Composition in Healthy Term Infants Fed Human Milk or Infant Formulas

    Time frame: 8 weeks

    stool composition: stool soap and non-soap fatty acids, total fatty acids, minerals, and other stool constituents

Secondary outcomes

  1. Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas

    Time frame: 8 weeks

    Determinations of fecal flora as well as fecal pH, sIgA concentrations and SCFA concentrations in a subset of subjects.

Other outcomes

  1. Safety evaluation

    Time frame: 10 weeks

    evaluation of adverse events

  2. Growth evaluation

    Time frame: 8 weeks

    Anthropometric measurements

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
May 23, 2013
Registry last updated
May 23, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.